Suppr超能文献

复杂腹主动脉瘤和胸腹主动脉瘤开窗分支型血管腔内修复术中髂股血管通道的结果

Outcomes of iliofemoral conduits during fenestrated-branched endovascular repair of complex abdominal and thoracoabdominal aortic aneurysms.

作者信息

Dias-Neto Marina, Marcondes Giulianna, Tenorio Emanuel R, Barbosa Lima Guilherme B, Baghbani-Oskouei Aidin, Vacirca Andrea, Mendes Bernardo C, Saqib Naveed, Mirza Aleem K, Oderich Gustavo S

机构信息

Department of Cardiothoracic and Vascular Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX.

Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN.

出版信息

J Vasc Surg. 2023 Mar;77(3):712-721.e1. doi: 10.1016/j.jvs.2022.10.050. Epub 2022 Nov 5.

Abstract

OBJECTIVE

To describe the technical pitfalls and outcomes of iliofemoral conduits during fenestrated-branched endovascular repair (FB-EVAR) of complex abdominal aortic aneurysms (CAAAs) and thoracoabdominal aortic aneurysms (TAAAs).

METHODS

We retrospectively reviewed the clinical data of 466 consecutive patients enrolled in a previous prospective nonrandomized study to investigate FB-EVAR for CAAAs/TAAAs (2013-2021). Iliofemoral conduits were performed through open surgical technique (temporary or permanent) in patients with patent internal iliac arteries or endovascular technique among those with occluded internal iliac arteries. End points were assessed in patients who had any iliac conduit or no conduits, and in patients who had conduits performed prior or during the index FB-EVAR, including procedural metrics, technical success, and major adverse events (MAE).

RESULTS

There were 138 CAAAs, 141 extent IV, and 187 extent I-III TAAAs treated by FB-EVAR with an average of 3.89 ± 0.52 vessels incorporated per patient. Any iliac conduit was required in 35 patients (7.5%), including 24 patients (10.4%) treated between 2013 and 2017 and 11 (4.7%) who had procedures between 2018 and 2021 (P = .019). Nineteen patients had permanent conduits using iliofemoral bypass, 11 had temporary iliac conduits, and 5 had endoconduits. Iliofemoral conduits were necessary in 12% of patients with extent I to III TAAA, in 6% with extent IV TAAA, and in 3% with CAAA (P = .009). The use of iliofemoral conduit was more frequent among women (74% vs 27%; P < .001) and in patients with chronic obstructive pulmonary disease (49% vs 28%; P = .013), peripheral artery disease (31% vs 15%; P = .009), and American Society of Anesthesiologists classification of III or higher (74% vs 51%; P = .009). There were no inadvertent iliac artery disruptions in the entire study. The 30-day mortality and MAE were 1% and 19%, respectively, for all patients. An iliofemoral conduit using retroperitoneal exposure during the index FB-EVAR was associated with longer operative time (322 ± 97 minutes vs 323 ± 110 minutes vs 215 ± 90 minutes; P < .001), higher estimated blood loss (425 ± 620 mL vs 580 ± 1050 mL vs 250 ± 400 mL; P < .001), and rate of red blood transfusion (92% vs 78% vs 32%; P < .001) and lower technical success (83% vs 87% vs 98%; P < .001), but no difference in intraoperative access complications and MAEs, compared with iliofemoral conduits without retroperitoneal exposure during the index FB-EVAR and control patients who had FB-EVAR without iliofemoral conduits, respectively. There were no differences in mortality or in other specific MAE among the three groups.

CONCLUSIONS

FB-EVAR with selective use of iliofemoral conduits was safe with low mortality and no occurrence of inadvertent iliac artery disruption or conversion. A staged approach is associated with shorter operating time, less blood loss, and lower transfusion requirements in the index procedure.

摘要

目的

描述在复杂腹主动脉瘤(CAAA)和胸腹主动脉瘤(TAAA)的开窗分支血管腔内修复术(FB-EVAR)中髂股管道的技术陷阱及结果。

方法

我们回顾性分析了466例连续患者的临床资料,这些患者参与了之前一项前瞻性非随机研究,该研究旨在探讨CAAA/TAAA的FB-EVAR(2013 - 2021年)。对于髂内动脉通畅的患者,通过开放手术技术(临时或永久性)建立髂股管道;对于髂内动脉闭塞的患者,则采用血管腔内技术。对有任何髂股管道或无管道的患者,以及在首次FB-EVAR之前或期间进行管道置入的患者进行终点评估,包括手术指标、技术成功率和主要不良事件(MAE)。

结果

通过FB-EVAR治疗了138例CAAA、141例IV型和187例I - III型TAAA,平均每位患者合并3.89±0.52支血管。35例患者(7.5%)需要置入任何类型的髂股管道,其中24例患者(10.4%)在2013年至2017年接受治疗,11例(4.7%)在2018年至2021年接受手术(P = 0.019)。19例患者使用髂股旁路建立永久性管道,11例使用临时髂股管道,5例使用血管腔内管道。I至III型TAAA患者中12%需要髂股管道,IV型TAAA患者中6%需要,CAAA患者中3%需要(P = 0.009)。女性(74%对27%;P < 0.001)、患有慢性阻塞性肺疾病(49%对28%;P = 0.013)、外周动脉疾病(31%对15%;P = 0.009)以及美国麻醉医师协会分级为III级或更高(74%对51%;P = 0.009)的患者中,髂股管道的使用更为频繁。在整个研究中未发生意外的髂动脉破裂。所有患者的30天死亡率和MAE分别为1%和19%。在首次FB-EVAR期间采用腹膜后暴露建立髂股管道与手术时间延长(322±97分钟对323±110分钟对215±90分钟;P < 0.001)、估计失血量增加(425±620毫升对580±1050毫升对250±400毫升;P < 0.001)、红细胞输血率升高(92%对78%对32%;P < 0.001)以及技术成功率降低(83%对87%对98%;P < 0.001)相关,但与首次FB-EVAR期间未采用腹膜后暴露建立髂股管道的患者以及未进行髂股管道置入的对照患者相比,术中入路并发症和MAE无差异。三组患者在死亡率或其他特定MAE方面无差异。

结论

选择性使用髂股管道的FB-EVAR安全,死亡率低,未发生意外的髂动脉破裂或中转开放手术。分期手术方法与首次手术中手术时间缩短、失血量减少和输血需求降低相关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验